Hirtle Callaghan & Co’s Novartis NVS Stock Holding History

Hirtle Callaghan & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7,147	Closed	-$593K	–	262
2014 Q4	$593K	Buy	7,147 +2,232	+45%	+$185K	0.14%	96
2014 Q3	$415K	Sell	4,915 -3,393	-41%	-$275K	0.07%	122
2014 Q2	$674K	Buy	8,308 +3,237	+64%	+$255K	0.09%	123
2014 Q1	$388K	Sell	5,071 -112	-2%	-$8.16K	0.06%	156
2013 Q4	$373K	Hold	5,183	–	–	0.05%	165
2013 Q3	$356K	Buy	+5,183	New	+$343K	0.06%	166

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Hirtle Callaghan & Co's NVS Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Novartis (NVS) in Q1 2015, closing a stake of 7,147 shares — an estimated $593K sold.

Hirtle Callaghan & Co first reported a position in NVS in Q3 2013 and held it in 6 quarters. The position peaked at $674K in Q2 2014. 940 funds tracked by Wall St. Rank hold NVS as of Q1 2015.

Hirtle Callaghan & Co reported no remaining Novartis position as of Q1 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 7,147 Novartis shares in Q1 2015, an estimated $593K.
Hirtle Callaghan & Co first reported a position in Novartis in Q3 2013 and held it in 6 quarters.
Hirtle Callaghan & Co's Novartis position peaked at $674K in Q2 2014.
940 funds tracked by Wall St. Rank held Novartis as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.